Nested Therapeutics Announces Nomination of First Development Candidate, a Potential First-in-Class Inhibitor of the RAS/MAPK Pathway

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers that were founded on the technology discovered by University researcher Kevan Shokat, PhD, today announced the nomination of the company’s first drug development candidate from its NEST-1 program, NST-628, a mechanistically novel non-degrading molecular glue that targets multiple nodes in the RAS/MAPK pathway.